Trial Profile
Nocturia QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Oxybutynin (Primary)
- Indications Nocturia; Overactive bladder
- Focus Therapeutic Use
- Acronyms NEOXY
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 03 Oct 2016 New trial record